GEN-MKT-18-7897-A
Mar 31, 2026 | Biopharma, BioPhase 8800 system, Blogs | 0 comments
Read time: 3 minutes
In monoclonal antibody (mAb) development, assessment of purity and integrity of the protein in question is critical. CE‑SDS is the gold standard assay and is routinely run from analytical development through QC and lot release. It’s trusted because it consistently delivers quantitative, size‑based insight into purity and fragmentation, and it fits naturally into regulated environments.
What continues to evolve with the changing drug landscape isn’t whether teams use CE‑SDS, but how much more they need from it: more confidence in low‑level species, less time spent wrestling with baselines and integration, and greater consistency across analysts, instruments, and sites.
This is where modern execution, and especially modern detection, start to matter.
CE‑SDS has earned its place as a foundational assay because it supports high‑value decisions throughout the mAb lifecycle:
Even for established programs, size and purity assessment still create persistent analytical pressure. Fragmentation, clipping, mispairing, and partial assembly are not rare events; they’re known risks that must be monitored and controlled.
CE‑SDS remains uniquely valuable because it provides complementary views under two common conditions:
As mAb formats expand and timelines tighten, teams increasingly rely on CE‑SDS not just to determine “what’s there,” but for trend confidence. Analytical teams need the ability to compare across runs, days, and sites without second‑guessing the data.
In many labs, CE‑SDS isn’t limited by separation efficiency. It’s limited by how confidently low‑abundance species can be detected and reliably quantified.
When detection baselines drift or noise complicates integration, analysts spend time:
While CE‑SDS is a well‑established workflow, native fluorescence detection (NFD) for CE‑SDS is a newer capability unique to the .
NFD leverages the intrinsic fluorescence of proteins to deliver label‑free detection with a cleaner baseline and improved sensitivity compared with traditional UV approaches, helping teams see low‑level species with greater confidence.
NFD can improve routine analysis by reducing ambiguity in peak detection and integration. It can match the sensitivity gained from LIF detection with dye, but without adding the sample preparation time and variability associated with labeling.
At SCIEX, NFD is available as a detection option on the BioPhase 8800 system , enabling teams to pair a trusted CE‑SDS workflow with a more sensitive, lower‑noise view of their data.
In a world where drug development programs move fast and data must travel across and throughout organizations, the analytical teams that win are the ones that generate results people can trust.
Teams don’t need to rethink whether CE‑SDS belongs in their control strategy. They need to ensure it continues to deliver what modern development demands:
That’s why the most impactful innovations in CE‑SDS today aren’t about replacing the workflow; they’re about improving how reliably and efficiently it performs.
CE‑SDS will remain the gold-standard assay for protein purity and integrity. The opportunity is to make it a higher‑confidence daily assay—by modernizing execution and adopting detection that helps visualize the information more clearly, earlier.
Watch our webinar: https://sciex.com/Hidden/landing-pages/nfd-launch-content-hub
Read the technical note: https://sciex.com/tech-notes/biopharma/intermediate-precision-study-of-ce-sds-assay-on-biophase8800-with-native-fluorescence-detection
Regulated laboratories are evolving faster than ever. New analytical modalities, higher sample throughput, increasing regulatory scrutiny, and leaner teams are reshaping how work gets done. At the same time, expectations for data integrity, standardization, and operational efficiency continue to increase complexity and/or scope. In this environment, LC-MS software is no longer simply an instrument control platform—it has become a critical part of a laboratory’s quality management system. The question is no longer whether your lab has changed, but whether your software has evolved to support the way regulated labs operate today, and if they are ready and able to meet the demands, they will face tomorrow.
Analyst software has long been a trusted foundation in regulated LC-MS laboratories—and for many, it still performs reliably today. But regulated environments are evolving faster than ever. As labs transition to Windows 11, strengthen cybersecurity policies, modernize IT infrastructure, and prepare for future compliance expectations, software decisions are no longer just about what works today—they’re about managing tomorrow’s risk. Analyst will not be supported on Windows 11. While some labs may continue operating in unsupported environments temporarily, the bigger question is: when that risk becomes reality, will your lab be reacting under pressure—or executing a planned mitigation strategy with confidence?
As regulatory scrutiny increases and detection requirements tighten, laboratories are facing a new question: How can TFA be measured reliably, sensitively, and at scale?
Posted by
You must be logged in to post a comment.
Share this post with your network